Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04085640
Other study ID # NOCH
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 14, 2020
Est. completion date September 22, 2020

Study information

Verified date December 2020
Source Clinique Medipole Garonne
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Interest of obturator nerve block for analgesia in total hip arthroplasty remains controversial. This regional anesthesia procedure could provide post-operative pain relief as obturator nerve is responsible for innervation of the internal part of the hip joint capsule. This randomized double-blind study aims to assess obturator nerve block for post-operative analgesia in total hip arthroplasty. Before the surgery, an ultrasound guided obturator nerve block will be performed with either 20cc of saline or ropivacaine 0.2% (a long-acting local anesthetics). After regional anesthesia, a general anesthesia will be performed for intraoperative period. This study aims to assess post-operative pain management during the first 24 hours. Ability to walk the day of the surgery will also be collected.


Description:

The best strategy to provide post-operative analgesia in total hip arthroplasty (THA) remains controversial. Many procedures have been descripted. Recent anatomical studies have reported that obturator nerve provide innervation of the internal part of the hip joint capsule. Obturator nerve block could be of major interest as it might improve post-operative analgesia without providing motor block of the quadriceps muscle. This could be associated with an early ability to walk and enhanced recovery. This randomized double-blind study aims to assess obturator nerve block after THA. After information, written informed consent will be obtained from all subjects before inclusion. At patient arrival in the anesthetic room, the research assistant will check the patient's consent. Using a computer-generated random number table, patients will be randomized in two-treatment groups by resource not part of the study. We have planned to include patients aged ≥18 years who were scheduled for primary THA under general anesthesia at the Elective Surgery Center, Clinique Medipole Garonne, Toulouse, France. The Elective Surgery Center annually performs approximately 1500 total hip arthroplasties. Exclusion criteria are revision of hip arthroplasty, pregnancy, breast feeding, significant psychiatric disturbances, history of relevant drug allergy, chronic pain, current use oral morphine or equivalents. Obturator nerve block will be performed before general anesthesia as descripted by Nielsen (RAPM, 2019). A linear transducer (X-Porte, Fujifilm SonoSite, Bothell, Washington, USA) will be oriented in the transverse plane and placed in the inguinal crease. The tail of the transducer will be tilted distal in order to visualize the pectineus muscle (medial to the femoral vessels) at its insertion at the superior pubic ramus superficial to the external obturator muscle. An 80 mm nerve block needle (SonoPlex, PAJUNK Medizintechnologie, Geisingen, Germany) will be inserted in-plane from the lateral end of the transducer and advanced until the tip of the needle will be inside the interfascial plane between the pectineus and the obturator externus muscles. 20 milliliters of either ropivacaine 2 mg/mL or isotonic saline-depending on random group allocation-will be injected in the interfacial plane between the pectineus and external obturator muscles. Medication will be prepared by a staff member who won't be involved in the study and delivered in unidentifiable syringes. As is common in our practice for patients undergoing THA, a standardized general anesthetic technique will be used for all patients including pre-administration of dexmedetomidine (1µg/kg) over 30 minutes, induction with ketamine (0.5 mg/kg), propofol (~3 mg/kg), and dexamethasone (0.15 mg/kg) and maintenance with continuous propofol (~7 mg/kg). All patients received a standardized intra-operative analgesic strategy including systemic acetaminophen 1000mg, ketoprofen 100mg and nefopam 20mg. A local infiltration of local anesthetics (ropivacaine 0.2%) will be performed by the surgeon as descripted by Kerr. The first injection will be performed into the tissues around the rim of the acetabulum, focusing on both the joint capsule if it remains, and around the exposed gluteal and adductor muscles. The second injection will be made into the external rotators, gluteus tendon, and iliotibial band. The third injection will be made into the subcutaneous tissues under the wound. In the post-anesthesia care unit (PACU), patients will be assessed for pain using a verbal rating scale (VRS) (VRS, 0=no pain, 10=worst pain). Patients suffering from pain (VRS > 4/10) will receive oxycodone 2 mg intravenous boluses / 3 minutes. Postoperative analgesic regimen for the first 24 hours' period will include acetaminophen 1000 mg orally every 6 hours, ibuprofen 400 mg orally every 8 hours and oxycodone 10 mg orally every 6 hours in case of VRS > 4/10. Pain and adverse effects will be assessed each 6 hours during the first 24 hours. The day of the surgery, the ability to ambulate will be assessed by physiotherapists using a 4 point scale (0: Unable to get up; 1: walk <10m; 2: walk between 10 - 50m; 3: walk > 50m). Patient's follow up ends at either the 24th hour of hospitalization or at patient discharge in day case surgery.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date September 22, 2020
Est. primary completion date September 22, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years and older - Primary THA under general anesthesia - Consent for participation - Affiliation to the french social security system Exclusion Criteria: - Revision of hip arthroplasty - Significant psychiatric disturbances - Minor patient - Pregnancy - Breastfeeding - Patient is in exclusion period as determined by previous study - Contraindication to any drug used in the protocol: acetaminophen, ketoprofen, nefopam, oxycodone, propofol, ketamine, Ropivacaine… - Chronic pain - Current use oral morphine or equivalents

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Obturator nerve block with ropivacaine 0.2%.
20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
Obturator nerve block with isotonic saline
20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles.

Locations

Country Name City State
France Clinique Medipole Garonne Toulouse

Sponsors (1)

Lead Sponsor Collaborator
Clinique Medipole Garonne

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Oxycodone requirement in PACU In the PACU, patients will be assessed for pain using a verbal rating scale (VRS) (VRS, 0=no pain, 10=worst pain). Patients suffering from pain (VRS > 4/10) will receive oxycodone 2 mg intravenous boluses / 3 minutes.
Oxycodone requirement will be compared between interventional and control groups.
Length of stay in PACU
Secondary Pain assessement Pain will be assessed every 6 hours using a VRS verbal rating scale ranging from 0 to 10 (0=no pain, 10=worst possible pain) Postoperative period : maximum 24 hours after surgery
Secondary Postoperative Oxycodone consumption Oxycodone requirement will be compared between interventional and control groups. Postoperative period : maximum 24 hours after surgery
Secondary Ability to walk The day of the surgery, the ability to ambulate will be assessed by physiotherapists using a 4-point scale (0: Unable to get up; 1: walk <10m; 2: walk between 10 - 50m; 3: walk > 50m). Postoperative period : maximum 24 hours after surgery
Secondary Side effects of opioids Collect side effects associated with Oxycodone: nausea/vomiting, dizziness, urinary retention Postoperative period : maximum 24 hours after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT03968939 - Total Joint Arthroplasty and Sleep Phase 4
Terminated NCT04036071 - Clinical Observation Study of the Hydroxylapatite-coated SLPLUS™MIA Hip Shaft
Completed NCT04209426 - Retrospective Observational Cohort Study of SYMBOL CUP DM 2
Enrolling by invitation NCT05313321 - Survival of the Insignia Stem in Total Hip Arthroplasty
Terminated NCT04121585 - Clinical Observation Study of the Hydroxylapatite-coated SL-PLUS™ Hip Shaft
Completed NCT03690037 - Investigating the Effect of Intravenous and Oral Tranexamic Acid on Blood Loss After Primary Hip and Knee Arthroplasty Phase 4
Completed NCT04209374 - Retrospective Observational Cohort Study of SYMBOL CUP DM 1
Completed NCT04122157 - Prospective Single-center Long-term Observation of the SL-PLUS® MIA Stem
Recruiting NCT04319952 - OPS™ With Direct Anterior Approach (DAA)
Completed NCT05072704 - Opioid Free Anesthesia in Total Hip Arthroplasty Phase 3
Completed NCT03973320 - Outcomes After Hypotensive Neuraxial Anesthesia in Total Hip Arthroplasty
Recruiting NCT01495546 - Total Hip Arthroplasty (THA): Early Load Versus Load Late N/A
Terminated NCT02933671 - Suprainguinal Fascia Iliaca (SIFI) Block Improves Analgesia Following Total Hip Arthroplasty Phase 4
Completed NCT03956381 - Accuracy of OPS™ Femoral Neck Resection Study